Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Adriamycin and its analogs].

F Arcamone

    Tumori
    |April 30, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Researchers developed second-generation anthracyclines, including epirubicin, idarubicin, and esorubicin, to improve upon existing chemotherapy drugs like doxorubicin. These new synthetic compounds show promise for cancer treatment with potentially altered pharmacological properties.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Studies on the chemistry of a glucoside a antibiotic from a Streptomyces sp.

    Antibiotics & chemotherapy (Northfield, Ill.)·2014
    Same author

    New TFO conjugates containing a carminomycinone-derived chromophore.

    Bioconjugate chemistry·2001
    Same author

    Configurational requirements of the sugar moiety for the pharmacological activity of anthracycline disaccharides.

    Biochemical pharmacology·2001
    Same author

    Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Reprinted from Biotechnology and Bioengineering, Vol. XI, Issue 6, Pages 1101-1110 (1969).

    Biotechnology and bioengineering·2000
    Same author

    Improved efficacy and enlarged spectrum of activity of a novel anthracycline disaccharide analogue of doxorubicin against human tumor xenografts.

    Clinical cancer research : an official journal of the American Association for Cancer Research·1998
    Same author

    Biosynthetic anthracyclines.

    Current medicinal chemistry·1998
    Same journal

    End-of-life decisions and opinions: Results of E.L.D.Y.-CA.RE study carried out at Veneto Institute of Oncology, Italy.

    Tumori·2026
    Same journal

    Quality indicators in identification and care of patients with genetic predisposition to cancer: An AIFET proposal.

    Tumori·2026
    Same journal

    Driver vs. passenger: Primary resistance to larotrectinib in synovial sarcoma harboring concurrent SS18 rearrangement and PDE3A-NTRK2 fusion.

    Tumori·2026
    Same journal

    Beyond the calendar: A narrative review on chronobiological drivers of prognosis in resectable NSCLC.

    Tumori·2026
    Same journal

    Challenging the cornerstone: Toward risk-adapted follow-up in early breast cancer.

    Tumori·2026
    Same journal

    Assessing in house comprehensive genomic profiling by liquid biopsy for NSCLC patients.

    Tumori·2026
    See all related articles

    Area of Science:

    • Biochemistry and Pharmacology
    • Medicinal Chemistry
    • Molecular Biology

    Context:

    • Adriamycin (doxorubicin) is a highly effective anthracycline anticancer drug produced by Streptomyces peucetius.
    • Low yields in adriamycin biosynthesis necessitate chemical conversion from daunorubicin.
    • A research program initiated in 1972 focused on developing second-generation anthracyclines.

    Purpose:

    • To discover and develop novel synthetic anthracyclines with improved therapeutic potential.
    • To investigate new analogs of daunorubicin and doxorubicin for cancer treatment.

    Summary:

    • Three new synthetic anthracyclines—4'-epidoxorubicin (epirubicin), 4-demethoxydaunorubicin (idarubicin), and 4'-deoxydoxorubicin (esorubicin)—were discovered.
    • These compounds exhibit DNA affinity similar to parent drugs but possess distinct pharmacological and metabolic profiles.

    Related Experiment Videos

  • The research outlines the discovery process and future directions for antitumor anthracyclines.

    • Impact:

    • Introduced novel synthetic anthracyclines (epirubicin, idarubicin, esorubicin) for clinical investigation.
    • These analogs offer potential alternatives to existing anthracyclines with modified properties.
    • Contributes to the ongoing advancement of anthracycline-based cancer chemotherapy.